Mizuho analyst Graig Suvannavejh upgraded Belite Bio (BLTE) to Outperform from Neutral with a price target of $194, up from $105. The firm cites the positive Phase 3 data for tinlarebant in Stargardt disease for the upgrade. The data are “impressive” and better than Mizuho’s expectations on both efficacy and safety, the analyst tells investors in a research note. The firm increased its probability of success assumptions for tinlarebant to 85% from 40%-60% prior. Mizuho sees the drug’s U.S. launch pricing at $350,000 and moved up its risk-unadjusted tinlarebant sales estimate to $4.2B. It sees further upside in the shares post the data.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio upgraded to Outperform from Neutral at Mizuho
- Belite Bio TBA Spot Secondary; price range $150.00-$154.00
- Belite Bio Reports Increased Cash Reserves Amid Rising R&D Costs
- Belite Bio Announces Public Offering of ADSs to Fund Expansion
- Belite Bio announces American Depositary shares offering, no amount given